UNSPSC 51171641: Polyethylene glycol

This classification denotes a synthetic polymer with the molecular formula C2H6O2(C2H4O)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B697894SGQ. European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. The term polyethylene glycol 400 is an International Nomenclature of Cosmetic Ingredients designation.

European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. Polyethylene glycol bears US NLM identifiers UMLS ID C0032483 and NCI Concept Code C762. SMILES: COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO.

UNSPSC 51171641 Polyethylene glycol (Commodity) comprises chemical compounds and precursor materials used in pharmaceutical manufacturing, drug testing, and medical specimen collection processes. State and local governments procure polyethylene glycol primarily as a component within broader pharmaceutical supply, drug screening, and clinical testing services rather than as a standalone chemical input. The code reflects materials embedded in specimen collection kits, immunoassay screening reagents, oral fluid testing solutions, and pharmaceutical formulations supplied through state health and human services departments, county criminal justice agencies, and cooperative purchasing alliances. Issuing bodies include county community supervision departments, state health and human services commissions, and multi-state cooperative purchasing organizations administering statewide and regional pharmaceutical procurement.

Recent activity concentrates in Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, plus three optional one-year renewals; the scope encompasses immunoassay screening, LC/MS/MS or GC/MS confirmation, oral fluid and hair testing, and electronic result reporting across two collection sites. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted March 27, 2026, due April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The Minnesota Department of Administration's Office of State Procurement, on behalf of MMCAP, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with contract effectiveness July 1, 2026 and a two-year term with optional extensions.